1. AWMF online. Available from: [Last accessed on 25 Apr 2019].

2. Bollen L, Wibmer C, Wang M, van der Linden YM, Leithner A, et al. Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases. Clin Exp Metastasis 2015;32:1-5.

3. Wang M, Jensen AB, Morgen SS, Wu CS, Sun M, et al. Survival analysis of breast cancer subtypes in patients with spinal metastases. Spine (Phila Pa 1976) 2014;39:1620-7.

4. Cardoso F, Costa A, Senkus E, Aapro M, André F, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 2017;28:3111.

5. Elkablawy MA, Albasri AM, Mohammed RA. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J 2016;37:137-41.

6. Feeley LP, Mulligan AM, Pinnaduwage D. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol 2014;27:554-61.

7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-47.

8. Harbeck N. Breast cancer: tumor biology-based concepts for surgical and drug treatment. Dtsch Med Wochenschr 2013;138:180-2. (in German)

9. Jiehua Li, Zhibai Chen, Ka Su, Jian Zeng. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol 2015;8:8500-5.

10. Kobayashi K, Ito Y, Matsuura M, Fukada I, Horii R, et al. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today 2016;46:821-6.

11. Putzier M, Haschke F. Diagnostic standards for extradural tumors and metastases of the spinal column. Orthopäde 2013;42:691-9. (in German)

12. Sciubba DM, Gokaslan ZL, Suk I, Suki D, Maldaun MV, et al. Positive and negative prognostic variables for patients undergoing spine surgery for metastatic breast disease. Eur Spine J 2007;16:1659-67.

13. Sciubba DM, Goodwin CR, Yurter A, Ju D, Ziya LG, et al. A systematic review of clinical outcomes and prognostic factors for patients undergoing surgery for spinal metastases secondary to breast cancer. Global Spine J 2016;6:482-96.

14. Sorlie T, Perou CM, Tibshirani R, Geisler S, Johnson H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.

15. Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med 2016;140:806-14.

16. Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop Scand 1995;66:143-6.

17. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, editor. Evaluation of Chemotherapeutic Agents. Columbia Univ Press; 1949. pp. 191-205.

18. Tokuhashi Y, Matsuzaki H, Oda H, Oshima M, Ryu J. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976) 2005;30:2186-91.

19. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, et al. Surgical strategy for spinal metastases. Spine (Phila Pa 1976) 2001;26:298-306.

20. Van der Linden YM, Dijkstra SPDS, Vonk EJ, Marijnen CA, Leer JW. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 2005;103:320-8.

21. Von der Höh NH, Gulow J, Tschöke SK, Völker A, Heyde CE. Prognosis scores for spinal metastases. Orthopäde 2013;42:725-33.

22. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.

23. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012;5:44.

24. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.

25. Coleman R, Powles T, Paterson A. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386:1353-61.

26. Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.

27. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.

28. Harbeck N, Rody A. Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer. J Clin Oncol 2012;30:686-9.

29. Crockard A, Bunger C, Harms J, Kawahara N, Mazel C, et al. Review of metastatic spine tumour classification and indications for surgery: the consensus statement of the global spine tumour study group. Eur Spine J 2010;19:215-22.

30. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52.

31. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J cancer 1984;34:323-8.

32. Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.

33. Sinn P, Aulmann S, Wirtz R, Schott S, Marmé F, et al. Multigene assays for classification, prognosis, and prediction in breast cancer: a critical review on the background and clinical utility. Geburtshilfe Frauenheilkd 2013;73:932-40.

34. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9.

35. Wang M, Bünger CE, Li H, Wu C, Høy K, et al. Predictive value of Tokuhashi scoring systems in spinal metastases, focusing on various primary tumor groups: evaluation of 448 patients in the Aarhus spinal metastases database. Spine (Phila Pa 1976) 2012;37:573-82.

36. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34.

37. Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.

38. Ulmer B, Richter M, Cakir B. The Tokuhashi score: significant predictive value for the life expectancy of patients with breast cancer with spinal metastases. Spine (Phila Pa 1976) 2005;30:2222-6.

39. Balain B, Jaiswal A, Trivedi JM, Eisenstein SM, Kuiper JH, et al. The Oswestry risk index: an aid in the treatment of metastatic disease of the spine. Bone Joint J 2013;95-B:210-6.

40. Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976) 1990;15:1110-3.

41. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983;16:87-101.

42. Fisher CG, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the spine oncology study group. Spine (Phila Pa 1976) 2010;35:E1221-9.

43. Harrington KD. Orthopedic surgical management of skeletal complications of malignancy. Cancer 1997;80:1614-27.

44. Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine (Phila Pa 1976) 1997;22:239-45.

45. Majeed H, Kumar S, Bommireddy R, Klezl Z, Calthorpe D. Accuracy of prognostic scores in decision making and predicting outcomes in metastatic spine disease. Ann R Coll Sure Engl 2012;94:28-33.

46. Bullmann V, Liljenqvist UR. Operative treatment of spinal metastases. Orthopaädie und Unfallchirurgie up2date 2010;5:279-94.

47. Heyde CE, Gulow J, von der Höh N, Völker A, Jeszenszky D, et al. Results-adapted operative treatment options for spinal metastases. Orthopäde 2013;42:734-45.

48. Von Salis-Soglio G, Prietzel T. Diagnostic methods in suspected malignant bone and soft tissue tumors. Orthopade 2002;31:595-607.

49. Cho JH, Ha JK, Hwang CJ. Patterns of treatment for metastatic pathological fractures of the spine: the efficacy of each treatment modality. Clin Orthop Surgn 2015;7:476-82.

50. Delank KS, Wendtner C, Eich HT, Eysel P. The treatment of spinal metastases. Dtsch Arztebl Int 2011;108:71-9.

51. Chen F, Xia YH, Cao WZ. Percutaneous kyphoplasty for the treatment of spinal metastases. Oncol Lett 2016;11:1799-806.

52. Josten C, Glasmacher S, Franck A. Indikationen und grenzen der minimal-invasiven stabilisierung der metastatisch befallenen wirbelsäule. Orthopäde 2013;42:755-64. Available from: [Last accessed on 17 Apr 2019].

53. Toquart A, Graillon T, Mansouri N. Management of spinal metastasis by minimal invasive surgery technique: surgical principles, indications: a literature review. Neurochirurgie 2016;62:157-64.

54. Utzschneider S, Weber P, Fottner, Wegener B, Jansson V, et al. Prognosis-adapted surgical management of bone metastases. Orthopäde 2009;38:308. 310-2, 314-5

55. Chiras J, Baragan H, Jean B, Rose M. Interventional radiology in bone metastases. Bull Cancer 2007;94:161-9.

56. Nakatsuka A, Yamakado K, Takaki H, Uraki J, Makita M, et al. Percutaneous radiofrequency ablation of painful spinal tumors adjacent to the spinal cord with real-time monitoring of spinal canal temperature: a prospective study. Cardiovasc Intervent Radiol 2009;32:70-5.

57. Zheng L, Chen Z, Sun M. A preliminary study of the safety and efficacy of radiofrequency ablation with percutaneous kyphoplasty for thoracolumbar vertebral metastatic tumor treatment. Med Sci Monit 2014;20:556-63.

58. Delgado-López PD, Rodríguez-Salazar A, Martín-Velasco V, Castilla-Díez JM, Martín-Alonso J, et al. Total en bloc spondylectomy for spinal tumours: technical aspects and surgical details. Neurocirugia 2017;28:51-66.

59. Gezercan Y, Çavuş G, Ökten AI. Single-stage posterolateral transpedicular approach with 360-degree stabilization and vertebrectomy in primary and metastatic tumors of the spine. World Neurosurg 2016;95:214-21.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: